ISORAY INC(NYSEARCA:ISR) stock News

ISR Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Perspective Therapeutics, Inc.

Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy

3 years ago - By: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer

3 years ago - By: Perspective Therapeutics, Inc.

Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

3 years ago - By: Perspective Therapeutics, Inc.

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

3 years ago - By: Isoray, Inc.

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

4 years ago - By: Benzinga

Recap: Isoray Q2 Earnings

3 years ago - By: Isoray, Inc. and Viewpoint Molecular Targeting, Inc.

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

3 years ago - By: Isoray, Inc.

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

3 years ago - By: Isoray, Inc.

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023

3 years ago - By: Isoray, Inc.

AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

3 years ago - By: Isoray, Inc.

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022

3 years ago - By: Benzinga - Mentions: VAPO RDW PRDS

Vapotherm, Redwire And These 2 Penny Stocks Insiders Are Aggressively Buying

3 years ago - By: Kahn Swick & Foti, LLC

ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

3 years ago - By: Isoray, Inc.

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

3 years ago - By: Isoray, Inc.

Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

3 years ago - By: Isoray, Inc. and Viewpoint Molecular Targeting, Inc.

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

3 years ago - By: Halper Sadeh LLC

ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders

3 years ago - By: Isoray, Inc.

Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

3 years ago - By: Isoray, Inc.

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

3 years ago - By: Isoray, Inc.

Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

3 years ago - By: Isoray, Inc.

Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference

3 years ago - By: Isoray, Inc.

Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

3 years ago - By: Isoray, Inc.

Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022

4 years ago - By: Isoray, Inc.

Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference

4 years ago - By: Isoray, Inc.

Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131

4 years ago - By: Isoray, Inc.

Isoray Announces Second Quarter Fiscal 2022 Financial Results

4 years ago - By: Isoray, Inc.

ISORAY INC (ISR) Stock News

ISR Latest News, Press Relases and Analysis

Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy

Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer

Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

Recap: Isoray Q2 Earnings

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023

AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022

Vapotherm, Redwire And These 2 Penny Stocks Insiders Are Aggressively Buying

ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders

Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference

Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022

Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131

Isoray Announces Second Quarter Fiscal 2022 Financial Results

Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022